anti-Lectin, Galactoside-Binding, Soluble, 8 (LGALS8) Antibodies

Mouse (Murine) Lectin, Galactoside-Binding, Soluble, 8 (LGALS8) interaction partners

1. these findings identify gal-8 as a new physiologic player in the regulation of bone mass.

2. Galectin-8 regulates antibacterial autophagy through differential recognition of host glycans on damaged phagosomes.

3. Galectin-8 activates dendritic cells and stimulates antigen-specific immune response elicitation.

4. these data suggest that Gal-8 promotes the differentiation of highly suppressive Treg cells, which has implications for the treatment of inflammatory and autoimmune diseases.

5. this study uncovers a unique molecular mechanism of lymphangiogenesis in which galectin-8-dependent crosstalk among VEGF-C, podoplanin and integrin pathways plays a key role.

6. Gal-8mut was unable to induce T-cell proliferation, but efficiently co-stimulated antigen-specific responses, bothin vitroandin vivo.

7. Gal-8 emerges as an attractive therapeutic candidate.

8. Galectin-8 induces RANKL expression, osteoclastogenesis, and bone mass reduction in mice.

9. Gal-8 stimulated naive T cells, but had an antiproliferative effect when these cells were activated.A dose of recombinant Gal-8 administered with a suboptimal Ag dose to DO11.10 mice strengthened weak responses in vivo.

10. a novel role for Gal-8 in collaboration with Gal-1 in plasma cell formation, and suggest the possibility of using distinct LacNAc ligands to modulate the function of Gals.

11. The findings of the present study delineate the differential molecular requirements for Gal-8 activities on T-cells, and suggest a dual activity relying on activation state.

12. galectin-8 is expressed in the thymus in mouse, which suggests an active role for this lectin in shaping the mature T cell repertoire

13. Taken together, our findings support a distinctive role for locally produced Gal-8 as an enhancer of otherwise borderline immune responses and also suggest that Gal-8 might fuel the reactivity at inflammatory foci.

Human Lectin, Galactoside-Binding, Soluble, 8 (LGALS8) interaction partners

1. Gal-8 also activates eNOS.

2. these findings demonstrate a central role of either ALCAM or Gal-8 (or both) in controlling triple negative breast cancer.

3. The study identified Gal-8 as a potent factor in osteoarthritis pathogenesis, acting in concert with Gal-1 and -3.

4. Inhibition of galectin-8- and NDP52-dependent autophagy increased seeded tau aggregation.

5. analysis of crystallographic structures of the galectin-8 N-terminal domain (galectin-8N) in complex with LNT and LNnT

6. Gal-8 served as a new positive prognostic factor for the OS and DFS of ovarian cancer patients.

7. We further demonstrated using the NMR-based hydrogen-deuterium exchange (HDX) that lactose binding increases the exchange rates of residues located on the opposite side of the ligand-binding pocket for hGal1 and hGal8(NTD), indicative of allostery. Additionally, lactose binding induces significant stabilisation of hGal8(CTD) across the entire domain

8. findings reveal that differential levels of Gal-3 and Gal-8 expression and recruitment to Group A streptococcus (GAS) between epithelial cells and endothelial cells may contribute to the different outcomes of GAS elimination or survival and growth of GAS in these two types of cells.

9. the natural and conserved expression of Gal-8 in tumour cells is responsible for the metastatic evolution of prostate cancer.

10. Both Gal-8 isoforms led to enhanced adhesion of myeloma cells to vascular endothelium under dynamic shear stress conditions, Gal-8L (by more than 40-fold) even stronger than Gal-8S.

11. Our data indicate that Gal-8 interacts with ALCAM at the surface of breast cancer cells through glycosylation-dependent mechanisms. A novel heterophilic interaction between ALCAM and Gal-8 is demonstrated here, suggesting its physiologic relevance in the biology of breast cancer cells

12. we detected Gal-8 in human cerebrospinal fluid, suggesting a role in the CNS immune-surveillance circuit. In addition, we show that MS patients generate function-blocking anti-Gal-8 antibodies with pathogenic potential. Furthermore, circulating anti-Gal-8 antibodies associate with relapsing-remitting MS, and not with progressive MS phenotypes, predicting clinical disability at diagnosis within the first year of follow-up

13. Data suggest that galectin-8 is a potential independent favorable prognostic biomarker for survival and recurrence of patients with gastric cancer after surgery.

14. this study uncovers a unique molecular mechanism of lymphangiogenesis in which galectin-8-dependent crosstalk among VEGF-C, podoplanin and integrin pathways plays a key role.

15. Platelet-derived factor V/Va is generated following endocytosis of the plasma-derived molecule by the platelet precursor cells, megakaryocytes, via a two receptor system consisting of LRP-1 and an unidentified specific "binding site".

16. Gal-8 expression is a potential independent unfavorable prognostic indicator for postoperative recurrence of patients with localized pT1 clear cell renal cell carcinoma

17. The fundamental roles of galectin-8 in human anaplastic large cell lymphoma

18. The implications of gal-8 in tumor angiogenesis remain to be further explored, but it is exciting to speculate that modulating gal-8-glycan interactions could be used to block lymphatic-vascular connections vital for metastasis

19. We integrate here the available information on Gal-8 expression in different tumor types and attempt to elucidate associations of its expression and localization with tumor progression[review]

20. these results not only confirm the pro-inflammatory role we have already proposed for Gal-8 in other cellular systems but also suggest that this lectin is orchestrating the interaction between leukocytes, platelets and endothelial cells